Development of PEGylated adenovirus vector with targeting ligand

被引:66
|
作者
Eto, Yusuke [1 ]
Yoshioka, Yasuo [1 ,2 ]
Mukai, Yohei [1 ]
Okada, Naoki [1 ]
Nakagawa, Shinsaku [1 ,2 ]
机构
[1] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biotechnol & Therapeut, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Ctr Adv Med Engn & Informat, Suita, Osaka 5650871, Japan
关键词
adenovirus vector; PEGylation; targeting;
D O I
10.1016/j.ijpharm.2007.08.025
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For effective gene therapy, a vector system that transduces the therapeutic gene into target cells efficiently and safely is essential. Adenovirus (Ad) vectors frequently are used for gene therapy research, especially cancer gene therapy, because of their high transduction efficiency. However, broad clinical utility of Ad vectors have not yet been achieved owing to problems related to several properties inherent to Ads. Systemic administration of Ad vectors leads to acute virus accumulation and undesirable transgene expression in the liver, with subsequent inefficient systemic cancer-targeted therapy and pronounced hepatotoxicity. Furthermore, most people have Ad-neutralizing antibodies, which hamper gene expression efficiency. Chemical conjugation of Ad surface with polyethylene glycol (PEG) (PEGylation) is one of the promising strategies to overcome these problems. Furthermore, PEGylation of Ad vectors with targeting ligands on the tip of PEG, which alter the transfection range of Ad vectors will improve the safety and efficiency of Ad gene-delivery vectors. In this review, we describe the molecular biology of Ads and outline this PEGylation approach including our data. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:3 / 8
页数:6
相关论文
共 50 条
  • [21] Adenovirus-Based Targeting in Myoblasts Is Hampered by Nonhomologous Vector Integration
    Isman, Olga
    Roberts, Michael L.
    Morgan, Jennifer E.
    Graham, Ian R.
    Goldring, Kirstin
    Lawrence-Watt, Diana J.
    Lu, Qi Long
    Dunckley, Matthew G.
    Porter, Andrew C. G.
    Partridge, Terence A.
    Dickson, George
    HUMAN GENE THERAPY, 2008, 19 (10) : 1000 - 1008
  • [22] Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration
    Gao, Jian-Qing
    Eto, Yusuke
    Yoshioka, Yasuo
    Sekiguchi, Fumiko
    Kurachi, Shinnosuke
    Morishige, Tomohiro
    Yao, Xinglei
    Watanabe, Hikaru
    Asavatanabodee, Ratima
    Sakurai, Fuminori
    Mizuguchi, Hiroyuki
    Okada, Yuka
    Mukai, Yohei
    Tsutsumi, Yasuo
    Mayumi, Tadanori
    Okada, Naoki
    Nakagawa, Shinsaku
    JOURNAL OF CONTROLLED RELEASE, 2007, 122 (01) : 102 - 110
  • [23] Adenovirus-5 Supported Replication of Subgroup F Adenovirus and Engineered Subgroup F Adenovirus Vector Targeting of Intestinal Mucosa
    Yamasaki, Satoshi
    Miura, Yoshiaki
    Brown, Eric
    Davydova, Julia G.
    Yamamoto, Masato
    MOLECULAR THERAPY, 2009, 17 : S324 - S324
  • [24] Development of adenovirus serotype 35 as a gene transfer vector
    Reddy, PS
    Ganesh, S
    Limbach, MP
    Brann, T
    Pinkstaff, A
    Kaloss, M
    Kaleko, M
    Connelly, S
    VIROLOGY, 2003, 311 (02) : 384 - 393
  • [25] Development of porcine adenovirus-3 as an expression vector
    Reddy, PS
    Idamakanti, N
    Hyun, BH
    Tikoo, SK
    Babiuk, LA
    JOURNAL OF GENERAL VIROLOGY, 1999, 80 : 563 - 570
  • [26] Development of Adenovirus serotype 10 as a vector for gene therapy
    Davies, James
    Uusi-Kerttula, Hanni
    Chester, John
    Parker, Alan
    HUMAN GENE THERAPY, 2017, 28 (08) : A29 - A29
  • [27] Development of Pancreatic tumor-targeting Oncolyic Adenovirus
    Aoki, Kazunori
    Yamamoto, Yuki
    Tagawa, Masatoshi
    CANCER SCIENCE, 2018, 109 : 961 - 961
  • [28] Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression
    Zhang, HG
    Bilbao, G
    Zhou, T
    Contreras, JL
    Gómez-Navarro, J
    Feng, MZ
    Saito, I
    Mountz, JD
    Curiel, DT
    JOURNAL OF VIROLOGY, 1998, 72 (03) : 2483 - 2490
  • [29] Targeting adenovirus
    Wickham, TJ
    GENE THERAPY, 2000, 7 (02) : 110 - 114
  • [30] Targeting adenovirus
    T J Wickham
    Gene Therapy, 2000, 7 : 110 - 114